- Trials with a EudraCT protocol (7)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
7 result(s) found for: Calcitonin gene-related peptide.
Displaying page 1 of 1.
EudraCT Number: 2020-000661-16 | Sponsor Protocol Number: CGRP2020 | Start Date*: 2020-06-18 | |||||||||||||||||||||
Sponsor Name:Rigshospitalet Glostrup | |||||||||||||||||||||||
Full Title: The effect of anti-calcitonin gene-related peptide (CGRP) receptor antibodies on the headache inducing properties of CGRP and cilostazol in migraine patients | |||||||||||||||||||||||
Medical condition: Migraine | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: DK (Completed) | |||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2021-000592-36 | Sponsor Protocol Number: CGRPAMS03 | Start Date*: 2023-07-10 | |||||||||||
Sponsor Name:Universitätsklinikum Essen | |||||||||||||
Full Title: Calcitonin Gene-Related Peptide Receptor Antagonists for Prevention of Acute Mountain Sickness | |||||||||||||
Medical condition: Acute Mountain Sickness (AMS) is a constellation of symptoms (headache, anorexia, nausea, vomiting, lightheadedness, and fatigue) occuring in unacclimatized mountaineers ascending too fast, too high | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-006176-16 | Sponsor Protocol Number: I5Q-NS-O001 | Start Date*: 2022-09-26 | |||||||||||
Sponsor Name:Charité - Universitätsmedizin Berlin | |||||||||||||
Full Title: Definition of neuroimaging and laboratory biomarkers as possible predictors for treatment response to Galcanezumab in high-frequency episodic migraine (PREDICT) | |||||||||||||
Medical condition: High-frequency episodic migraine. | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2005-005638-10 | Sponsor Protocol Number: SST-Pr-2-2005 | Start Date*: 2007-02-12 | |||||||||||
Sponsor Name:University of Münster | |||||||||||||
Full Title: Evaluation of the antipruritic effect of Elidel (pimecrolimus) in non-atopic pruritic disease | |||||||||||||
Medical condition: Prurigo nodularis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-004622-28 | Sponsor Protocol Number: I5Q-MC-CGAT | Start Date*: 2021-02-22 | |||||||||||
Sponsor Name:Eli Lilly and Company | |||||||||||||
Full Title: A Randomized, Double-Blind, Placebo-Controlled Study of Galcanezumab in Adolescent Patients 12 to 17 Years of Age with Chronic Migraine – the REBUILD-2 Study | |||||||||||||
Medical condition: Chronic Migraine | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Trial now transitioned) DE (Completed) FR (Trial now transitioned) IT (Trial now transitioned) NL (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-004351-23 | Sponsor Protocol Number: I5Q-MC-CGAS | Start Date*: 2021-02-22 | |||||||||||
Sponsor Name:Eli Lilly and Company | |||||||||||||
Full Title: A Randomized, Double-Blind, Placebo-Controlled Study of Galcanezumab in Patients 6 to 17 Years of Age with Episodic Migraine – the REBUILD-1 Study | |||||||||||||
Medical condition: Episodic Migraine | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Trial now transitioned) DE (Completed) IT (Trial now transitioned) NL (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-004337-32 | Sponsor Protocol Number: 3101-303-002 | Start Date*: 2020-02-12 | |||||||||||
Sponsor Name:Allergan Limited | |||||||||||||
Full Title: A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF ATOGEPANT FOR THE PREVENTION OF CHRONIC MIGRAINE (PR... | |||||||||||||
Medical condition: Chronic migraine | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) CZ (Completed) SE (Completed) PL (Completed) DE (Completed) DK (Completed) ES (Completed) GB (GB - no longer in EU/EEA) IT (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
